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the glycogen-hydrolyzing lysosomal enzyme acid a-glucosidase
(GAA), which leads to progressive muscle wasting. This auto-
somal-recessive disorder is the result of disease-associated
variants located in the GAA gene. In the present study, we per-
formed extended molecular diagnostic analysis to identify
novel disease-associated variants in six suspected Pompe
patients from four different families for which conventional
diagnostic assays were insufﬁcient. Additional assays, such as
a generic-splicing assay, minigene analysis, SNP array analysis,
and targeted Sanger sequencing, allowed the identiﬁcation of
an exonic deletion, a promoter deletion, and a novel splicing
variant located in the 50 UTR. Furthermore, we describe the
diagnostic process for an infantile patient with an atypical
phenotype, consisting of left ventricular hypertrophy but no
signs of muscle weakness or motor problems. This led to the
identiﬁcation of a genetic mosaicism for a very severe GAA
variant caused by a segmental uniparental isodisomy (UPD).
With this study, we aim to emphasize the need for additional
analyses to detect new disease-associated GAA variants and
non-Mendelian genotypes in Pompe disease where conven-
tional DNA diagnostic assays are insufﬁcient.Received 9 November 2019; accepted 31 December 2019;
https://doi.org/10.1016/j.omtm.2019.12.016.
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Pompe disease (glycogen storage disease type II, OMIM 232300) is a
rare metabolic disorder that leads to progressive muscle wasting
caused by acid a-glucosidase (GAA) enzyme deﬁciency. This auto-
somal-recessive disorder is caused by disease-associated variants
located in the GAA gene.1 Classic infantile Pompe patients have a
complete deﬁciency of GAA enzymatic activity and present hypertro-
phic cardiomyopathy and severe muscle weakness shortly after birth.
Patients with residual GAA activity can be classiﬁed as childhood- or
adult-onset Pompe patients, based on the age at symptom onset, and
generally do not show cardiac involvement.Molecular Therapy: Methods &
This is an open access article under the CC BY-NC-Enzyme replacement therapy (ERT) is currently the only available
treatment. Without treatment, classic infantile Pompe patients do
not survive the ﬁrst year of life due to cardiorespiratory failure.2,3
In order to become eligible for ERT, a patient needs to present a clin-
ical phenotype related to Pompe disease and have a GAA deﬁciency,
and certain countries require the identiﬁcation of two disease-associ-
ated variants in the GAA gene.4 GAA activity measurements are
performed using dried blood with spot sampling or with primary
ﬁbroblasts or leukocytes using either glycogen or 4-methylumbellifer-
one-a-d-glucopyranoside (4MU) as a substrate.5 False-positive
results are known to occur using blood-based assays, for example,
those caused by known pseudodeﬁciency alleles; therefore,
DNA analysis is recommended in order to identify disease-associated
variants.5–7 Routine diagnostic DNA analysis usually focuses
only on the coding regions of GAA using PCR reactions and subse-
quent Sanger sequencing.6,8 This method detects variants in the
coding regions and in close proximity to splice sites but not in the
promoter, UTRs, and most of the intronic regions.4,9 Reported
variants are listed in the “Pompe disease GAA variant database”
(http://www.pompevariantdatabase.nl), which contains over 400 dis-
ease-associated variants in GAA and has4 recently been extended to
include clinical phenotypes.10 When the disease-associated variants
of both alleles are identiﬁed using DNA sequencing, a general predic-
tion of the patient phenotype is possible using the information in this
database. Recent ﬁndings indicate that analysis of the modiﬁer
c.510C> T variant, which is silent but modulates splicing in patients
carrying the common c.-32-13T>G (IVS1) variants, is also
important.11Clinical Development Vol. 17 June 2020 ª 2020 The Author(s). 337
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1. Basic Information for All Patients at Start of Analysis
Age at Symptom
Onset
GAA Activity in Fibroblasts
(Patient Range: 0–20 nmol/h/mg)
Disease-Associated
Variant 1
Disease-Associated
Variant 2 Initial Symptoms
Patient 1 <1 month 0 nmol/h/mg
c.2331+2T>A
p.0?
? muscle weakness and cardiomyopathy
Patient 2 15 years 13.7 nmol/h/mg
c.-32-13T>G
p.=, p.0?
? muscle weakness
Patient 3 (sibling 1) 24 years 7.5 nmol/h/mg
? + c.2065G>A
? + p.(Glu689Lys)
? + c.2065G>A
? + p.(Glu689Lys)
general fatigue
Patient 4 (sibling 2) 41 years deﬁcient in lymphocytes
? + c.2065G>A
? + p.(Glu689Lys)
? + c.2065G>A
? + p.(Glu689Lys)
muscle weakness and general fatigue
Patient 5 (sibling 3) 21 years deﬁcient in lymphocytes
? + c.2065G>A
? + p.(Glu689Lys)
? + c.2065G>A
? + p.(Glu689Lys)
muscle weakness and general fatigue
Patient 6 <1 month 8.1 nmol/h/mg
c.925G>A
p.(Gly309Arg)
? left ventricular hypertrophy
Molecular Therapy: Methods & Clinical DevelopmentPreviously, we described an exon-ﬂanking RT-PCR that can be used
to detect novel disease-associated variants that affect pre-mRNA
splicing, irrespective of their location.9,12 This assay is important
for diagnosis but also to allow the design of antisense oligonucleotides
that can restore splicing.12–15 Other work has shown single-nucleo-
tide polymorphism (SNP) array analysis to be capable of explaining
phenotypes by detecting large deletions or genomic copy number var-
iations (CNVs).16–18 In addition, SNP array analysis can be used to
elucidate homozygote variants incompatible with Mendelian inheri-
tance by detecting uniparental isodisomies (UPDs) and regions of ho-
mozygosity (RoHs).16,17
Here, we utilized the additional diagnostic assays described above to
identify the genetic cause of Pompe disease in six patients from four
families with incomplete DNA sequencing results. This resulted in the
identiﬁcation of three novel disease-associated variants located in
non-coding regions of GAA. Additionally, we describe the genetic
analysis performed for a patient with an atypical Pompe phenotype,
ﬁrst described in Labrijn-Marks et al.17 We provide the clinical symp-
toms and the series of experiments that were performed in order to
make this diagnosis and to strengthen the conclusion that this is a
mosaic patient.
RESULTS
The six patients (including three siblings) described here had symp-
toms that could be attributed to a GAA deﬁciency. Enzymatic activity
of GAA was found deﬁcient in primary ﬁbroblasts and indicated that
Pompe disease is a probable cause of symptoms. Genetic screenings of
the coding regions of GAA were insufﬁcient to provide a genotype
that corresponds with the observed phenotype (Table 1).
Patient 1
The ﬁrst indication of Pompe disease was observed during prenatal
ultrasound, which found evidence of cardiac hypertrophy. Muscle
weakness presented shortly after birth, and cultured primary ﬁbro-
blasts showed no GAA enzyme activity (Table 1). Sanger sequencing
of the coding regions identiﬁed the heterozygous c.2331+2T>A338 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2variant (Table 1; Figure 1A). The intronic c.2331+2T>A variant has
been classiﬁed as “very severe” and is associated with the classic infan-
tile phenotype when combined with a null allele.10,19 This variant is
located close to the exon 16 splice donor site and affects splicing of
intron 16, ultimately resulting in a frameshift, the generation of an
early stop codon, and mRNA degradation. The second disease-asso-
ciated variant was not identiﬁed by standard DNA sequencing.
Exon-ﬂanking RT-PCR for all GAA exons was performed as previ-
ously described9 to test for the presence of a non-coding intronic
variant and revealed an aberrant product of exons 8, 9, and 10 (Fig-
ure 1B; product 2). Sanger sequence analysis of this product showed
the exclusion of exon 9 from the transcripts, but it failed to identify a
candidate splicing variant around the splice junctions (Figure 1C). To
test the possibility of a deletion that could have been obscured by the
presence of the other allele, we performed ﬂanking exon PCR analysis
of exon 9 (ranging from exon 8 to exon 10) using genomic DNA as a
template (Figure 1D). This showed the presence of an additional band
in the patient DNA that was not found in the healthy control, one that
corresponded with the expected product ranging from exon 8 to 10
and one that contained a 343-bp deletion that spanned exon 9 and
parts of the neighboring introns (band A in Figure 1E).
The resulting c.1327-61_1437+171del variant explains the exclusion
of exon 9 at the RNA level and why the initial DNA sequencing anal-
ysis was unable to detect this variant, as the annealing sites for PCR
ampliﬁcation were included in the deleted region. The deletion of
exon 9 has been shown to result in a total disruption of GAA
enzyme activity in previous work.9 The combination of c.1327-
61_1437+171del and c.2331+2T>A explains the lack of enzyme
activity and the classic infantile phenotype of the patient (Figure 1F).
Patient 2
The second patient presented mild muscle weakness at 15 years of
age. GAA activity in ﬁbroblasts was found to be reduced to
13.7 nmol/h/mg (patient range: 0–20 nmol/h/mg). Sanger sequencing
analysis performed on the patient’s DNA identiﬁed the c.-32-13T>G020
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Figure 1. Identification of a Disease-Associated Deletion in Patient 1 Using the Splicing Assay
(A) Genotype of patient 1 at the start of analysis. (B) Splicing assay for GAA exons 2–19 performed on cDNA obtained from fibroblasts. Bands marked 1. and 2. indicate two
different products detected around exon 9. (C) Cartoons of products 1 and 2 identified using Sanger sequencing of the PCR product. (D) PCR product from GAA exon 8 to
exon 10, performed on DNA. A., An additional band from patient 1 that was 343 bp smaller compared to the normal product; *, non-specific bands as a result of the PCR. (E)
Sanger sequencing of product A. The new junction resulting from the deletion is indicated. (F) Cartoon of both disease-associated variants identified in patient 1.
www.moleculartherapy.org(IVS1) variant in a heterozygous state but failed to identify a second
disease-associated variant (Table 1; Figure 2A)
Exon-ﬂanking RT-PCR of cDNA, derived from the patient’s ﬁbro-
blasts, showed no aberrant splicing products, except for those
caused by the IVS1 variant around exon 2 (Figure 2B).13,20,21
Next, we performed SNP array analysis to test for the presence of
large genomic aberrations. This analysis revealed a deletion on chro-Moleculmosome 17 (GRCh37/hg19 [Chr17:78.059.821–78.076.592]) (Fig-
ure 2C). Further evaluation of this 17kb deletion indicated that it
starts upstream of GAA in the CCDC40 gene and included the pro-
moter, transcription start site (TSS), and non-coding exons 1A and
1B of GAA.
Formally proving the pathogenicity of this deletion was compli-
cated, due to the residual GAA expression and activity originatingar Therapy: Methods & Clinical Development Vol. 17 June 2020 339
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Figure 2. Identification of a GAA Promoter Deletion in Patient 2 Using a SNP Array
(A) Genotype of patient 2 at the start of analysis. (B) Splicing assay forGAA exons 2–19 performed on cDNA obtained from fibroblasts. *Knownmis-spliced transcripts caused
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Cartoon of both disease-associated variants identified in patient 2.
Molecular Therapy: Methods & Clinical Developmentfrom the IVS1 allele. To address this, the sequence of exon 3 in the
patient’s DNA and mRNA was analyzed for allele-speciﬁc SNPs
(Figure 2D). We identiﬁed the c.596A>G SNP (rs1042393, minor
allele frequency [MAF] in Dutch population: 75%) in a heterozy-
gous state in the patient’s DNA.22 With the use of an IVS1-speciﬁc340 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2PCR (Figure S1), we found the c.596A>G SNP not to be present on
the allele containing the IVS1 variant. Sequence analysis of the
cDNA failed to detect transcripts that contained the c.596A>G
SNP, indicating that the allele containing the deletion is not
expressed.020
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Molecular Therapy: Methods & Clinical DevelopmentIn conclusion, the 17kb deletion, including the promoter and TSS,
completely abrogates GAA expression, and the combination with
the late-onset IVS1 variant on the other allele (Figure 2E) explains
the late-onset phenotype presented by the patient.Patients 3, 4, and 5
Patients 3, 4, and 5 are siblings, all of whom showed progressive mus-
cle weakness later in life. Primary ﬁbroblasts were only available for
patient 3. GAA activity in lymphocytes was deﬁcient in all three sib-
lings; this was conﬁrmed in the primary ﬁbroblasts of patient 3 (Table
1). Sanger sequence analysis revealed the 2065G>A variant in a ho-
mozygous state for all three siblings but was unable to identify any
disease-associated variants (Figure 3A). Previous work has shown
that the c.2065G>A variant reduces GAA activity to 54% in a GAA
cDNA expression construct.23 This reduction is not sufﬁcient for a
patient to present symptoms associated with Pompe disease but is
known to lead to a pseudodeﬁciency of GAA.23
Exon-ﬂanking RT-PCR of cDNA derived from ﬁbroblasts of patient
3 did not detect any aberrant splicing events but showed an overall
low expression of GAA (Figure 3B). Quantitative real-time PCR
(qRT-PCR) analysis conﬁrmed this, showing a reduction of GAA
expression to 8% of healthy control values (Figure 3C). SNP array anal-
ysis showed several large RoHs in all siblings that were likely derived
from regions that were homologous in both parents, suggesting con-
sanguinity between the parents. Interestingly, all three siblings were
found to have a RoH ranging from 17q25.3 to the 17qter (including
GAA) but this was not present in the paternal DNA (Figure 3D; Fig-
ure S2). The consanguinity of the parents explains the presence of
the multiple RoHs in the three siblings via a combination of several
identical blocks. However, this ﬁnding does not explain the decreased
expression of GAA mRNA, and we hypothesized the presence of a
variant in the 50 UTR or the promoter. To this end, Sanger sequencing
was performed for the non-coding ﬁrst exons and the GAA promoter
(Figure 3E). Sanger sequence analysis of this region revealed the pres-
ence of the homozygous variant c.-113+2T>A in patient 3. This variant
is located close to the splice acceptor of exon 1A, which is, according to
recent annotations, the 50 part of exon 1. Our unpublished RNA
sequencing (RNA-seq) data indicate that in agreement with the recent
annotations, exon 1 consists of two small exons (exon 1A and exon 1B)
that are spliced in cells from healthy individuals, as well as patients with
Pompe disease. The c.-113+2T>A variant was also found in a homozy-
gous state in the two siblings (patients 4 and 5) and in a heterozygousFigure 3. Identification of a RoH and a Novel Splicing Variant in Exon 1A in Pat
(A) Genotype of patient 3 at the start of analysis. (B) Splicing assay forGAA exons 2–19 perf
performed on cDNA obtained from fibroblasts, normalized for GAPDH. Significance com
segment of chromosome 17 showing absence of deletions or duplications (top) and a RoH
presence of the c.-113+2T>A variant. (F) Cartoon of the generated constructs ranging from
exon 2 performed on cDNA obtained fromHEK293T cells after transfection with the minig
0.001. (H) RT-PCRs performed oncDNAobtained from transfectedHEK293T. RT-PCR ran
With an accompanying cartoon for the RT-PCRs, the location of the primers are indicat
pseudodeficiency variant c.2065G>A, both at a homozygous state in patient 3. Error bar
342 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2state in paternal DNA. This variant has not been described previously.
DNA from the mother was unavailable.
To investigate the pathogenic nature of c.-113+2T>A, a previously
published minigene model was modiﬁed to include the genomic
region of exon 1A.12 Two new constructs were generated, one wild-
type and one carrying the c.-113+2T>A variant (Figure 3F). qRT-
PCR of cDNA obtained from transfected HEK293T cells using
primers located in exon 2 showed that c.-113+2T>A reduced GAA
expression to 35% of the wild-type minigene (Figure 3G). Exon-ﬂank-
ing PCR for exons 1 to 3 showed that c.-113+2T>A lowered expres-
sion of mRNA containing exon 1B-exon 3 (Figure 3H, left panel). An
additional exon-ﬂanking RT-PCR was performed to detect aberrant
splicing events between exons 1A and 1B (Figure 3H). The wild-
type construct spliced both exons correctly, whereas the mutant
completely abolished expression of the mRNA transcript containing
the exon 1A-exon 1B splice junction (Figure 3H). We note that we
were unable to test these splicing events in patient ﬁbroblasts due
to the low expression of GAA mentioned previously.
In summary, the c.-113+2T>A variant decreases expression of GAA.
We note that the reduction in the minigene was less strong (65%)
compared to the reduction in ﬁbroblasts (92%). This difference might
be due to promoter-dependent effects of the c.-113+2T>A variant, as
in the patient’s ﬁbroblasts, mRNA expression is regulated by the
endogenous GAA promoter, whereas expression from the minigene
model is regulated by the cytomegalovirus (CMV) promoter. Addi-
tionally, all three patients carry both the c.-113+2T>A and
c.2065G>A variants at a homozygous state (Figure 3I). The
c.2065G>A missense variant is known to decrease activity to
50%.23 The combined action of both variants likely reduces endog-
enous GAA activity to pathogenic levels.
Patient 6
Indications for a superior vena cava syndrome were found during a
routine prenatal ultrasound. Further cardiac screening was performed
at the age of 2.5 months and revealed a left ventricular hypertrophy
(LVH) with cardiac ultrasound, whereas electrocardiography showed
a shortened PQ interval time without signs of pre-excitation (Table
2). At this time, the patient was normotonic with good psychomotor
development and showed no signs of muscle weakness. Exome
screening of cardiac genes was negative, and a metabolic examination
of plasma and urine showed mildly elevated creatine kinase (CK) and
transaminase levels. GAA activity was found to be only slightlyients 3–5
ormed on cDNAobtained from fibroblasts frompatient 3. (C) qRT-PCR results forGAA
paring healthy control and patient 3: p < 0.001. (D) SNP array result visualized for a
from17q25.3 to 17qter (bottom). (E) Sanger sequencing of exon 1, demonstrating the
GAA exon 1A to exon 3,with the c.-113+2T>A variant indicated. (G) qRT-PCRofGAA
enemodel. Results are normalized for neomycin. All comparisons were significant: p <
ging fromexon 1b to exon 3 (left) andRT-PCR for the exon1a–1b splice junction (right).
ed using arrows. (I) Cartoon of the disease-associated variant c.-113+2T>A and the
s in C and G indicate standard deviation (S.D.)
020
c.925G>A in cDNA from cultured fibroblasts
AC GA CCCC CGG G G G G TTT TT TG
91M 1817161514131211109876543 M2
GAA Exon number
(BP)
3000
2000
1000
850
650
500
400
300
200
100
1650
A
B C
CC TT
CC T
CC TT
c.925G>A in DNA from leukocytes
c.925G>A in DNA from cultured fibroblasts
AC GAC C CG GGG G G TTTT
G
c.925G>A in DNA from skeletal muscle
AC GAC C CG GGG G G TTT TT
G
AC GAC C CG GGG G G TTTT G
location probe
17p12 (green) 96% (400) 99.5% (200) 98% (200)
17q22 (red) 95% (200) 95.5% (200) 97.5% (200)
Patient (n) Pompe control (n) Healthy control (n) 
C
hr
17
 in
 le
uk
oc
yt
es
C
hr
17
 in
 fi
br
ob
la
st
s
ΔBAF 17%
ΔBAF 25%
Patient 6: 5 64
c.925G>A
Allele 1
Allele 2 ?
Patient 6:
5 64
c.925G>A
Allele 1
Allele 2 5 64
c.925G= /G>A
D
F
H
GE
Pa
tie
nt
 6
Cl
as
sic
 in
fa
nt
ile
Ch
ild
ho
od
 p
at
ien
t
Ad
ul
t p
at
ien
t
He
alt
hy
 co
nt
ro
l
0
50
100
150 GAA activity 
G
A
A
 a
ct
iv
ity
 (%
 o
f c
on
tr
ol
)
Pa
tie
nt
 6
Cl
as
sic
 in
fa
nt
ile
Ch
ild
ho
od
 pa
tie
nt
Ad
ul
t p
at
ien
t
He
alt
hy
 co
nt
ro
l
0
200
400
600
800
1000 glycogen accumulation
gl
yc
og
en
 (μ
g/
m
g 
pr
ot
ei
n)
(legend on next page)
www.moleculartherapy.org
Molecular Therapy: Methods & Clinical Development Vol. 17 June 2020 343
Table 2. Clinical and Molecular Information Accompanying Patient 6
Patient Information
Age at analysis 2.5 months to 4 years
Gender male
GAA Activity Patient Range
Fibroblasts 8.1 nmol/h/mg 0–20 nmol/h/mg
Leukocytes 26 nmol/h/mg 0–10 nmol/h/mg
Clinical Description
Left ventricular hypertrophy detected
No signs of respiratory insufﬁciency
No muscle weakness
Cardiac Muscle Measurements
Left ventricular mass 122.1 g (Z score +3.7)
Shortening fraction 37.1% (Z score +0.14)
CK levels 243 U/L (ref < 230 U/L)
Disease-Associated Variants
Allele 1 c.925G>A
Allele 2 no variant found
Parental Disease-Associated Variants
Father (Asymptomatic)
Allele 1 c.925G>A
Allele 2 no variant found
Mother (Asymptomatic)
Allele 1 no variant found
Allele 2 no variant found
SNP Array Result
Segmental abnormality range: Chr17:41.681.527–Chr17qter
Molecular Therapy: Methods & Clinical Developmentdecreased in leukocytes, whereas in primary ﬁbroblasts, enzymatic ac-
tivity was within the range of late-onset Pompe disease (Table 2).17
Histochemical analysis of a muscle biopsy showed normal
morphology, but some enlarged lysosomes were visible using acid
phosphatase staining (Figure S3). In addition, periodic acid-Schiff
(PAS) staining showed minor glycogen accumulation (Figure S3).
These ﬁndings suggested that the patient might have late-onset
Pompe disease,24 but there were two inconsistencies: the lack of
GAA deﬁciency in lymphocytes and the LVH, a characteristic of
the classic infantile phenotype but not late-onset Pompe disease.Figure 4. Identification of a Mosaic Segmental UPD in Patient 6
(A) Genotype of patient 6 at the start of analysis. (B) Splicing assay for GAA exons 2–1
c.925G>A variant performed on cDNA obtained from fibroblasts. (D) SNP array analysis
(bottom). DBAF indicates the estimated difference in BAF between the affected and unaffe
obtained from leukocytes (top), fibroblasts (middle), or skeletal muscle tissue (bottom). (F)
17q22 (red) and 40,6-diamidino-2-phenylindole (DAPI) staining to highlight the cell nucleus.
Biochemical quantification of GAA activity measured using 4MU as a substrate. Significan
classic infantile and healthy control: p = 0.01. (G, bottom)Measurements of intracellular glyc
control samples: p < 0.01. Comparison of patient 6 and all other samples: not significant (
protein extracts obtained from fibroblasts after culturing to confluence for 3 weeks, follo
percentage of the healthy control fibroblasts. (H) Cartoon of both disease-associated var
344 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2Sanger sequencing revealed only the disease-associated variant
c.925G>A at a heterozygous state (Figure 4A). This variant is associ-
ated with the classic infantile phenotype when combined with a null
allele.25,26 Sanger sequence analysis of the parents (both showed no
signs of Pompe disease) found the c.925G>A only in a heterozygous
state in paternal DNA. No other disease-associated variants were
identiﬁed in the patient nor in his parents (Table 2). Exon-ﬂanking
RT-PCR of cDNA from primary ﬁbroblasts of the patient did not
detect any splicing aberrations (Figure 4B). Sequence analysis of the
GAA mRNA transcripts showed that the majority of transcripts con-
tained the c.925G>A variant (Figure 4C). This indicated that the sec-
ond GAA allele was present but was expressed at reduced levels. SNP
array analysis identiﬁed a 39.5-Mb allelic imbalance, ranging from
17q21.31 to the 17qter (Figure 4D).17 The imbalance showed no
change in CNV but a change in chromosomal equilibrium (i.e., a
change in the B allele frequency of heterozygous SNPs) for SNPs
located in the affected segment.17 Within the imbalanced segment,
GAA was present, whereas all other genes present within this region
were unlikely to be the cause of the presented phenotype (Table S1).27
When analyzing the SNP array data, it became clear that the allelic
imbalance was more profound in ﬁbroblasts compared to leukocytes.
We estimated a deviation in B allele frequency (DBAF) of ±25% in ﬁ-
broblasts compared to ±17% in leukocytes (Figure 4D). This was
consistent with the GAA activity, which showed that activity in ﬁbro-
blasts was lower compared to leukocytes (Table 2).
Additional Sanger sequence analysis of the patient’s tissues showed a
skewed contribution in favor of the c.925A variant in primary ﬁbro-
blasts, leukocytes, and also in skeletal muscle tissue (Figure 4E).
Microsatellite analysis of chromosome 17 showed a skewed composi-
tion in favor of the paternal allele in the affected segment, whereas
markers located in the unaffected segmentwere distributed evenly (Fig-
ure S4). Fluorescence in situ hybridization (FISH), using probes located
on 17p12 and 17q22 to detect both ends of chromosome 17, showed a
normal karyotype in the patient’s ﬁbroblasts (Figure 4F). Both ends of
the chromosome were present at equal numbers, conﬁrming that this
imbalance is not the result of a change in genomic copy number.
The results are in line with a mosaic segmental UPD, in which
affected cells contain two copies of the paternal GAA that harbor
the c.925G>A variant. The patient’s tissue is comprised of two distinct
cell populations: one with the c.925G>A variant in a homozygous
state, resulting in a classic infantile Pompe genotype, and one with9 performed on cDNA obtained from fibroblasts. (C) Sanger sequencing around the
of chromosome 17 performed on DNA obtained from leukocytes (top) or fibroblasts
cted segment. (E) Sanger sequencing around the 925G>A variant performed on DNA
FISH analysis performed in fibroblasts showing probes located on 17p12 (green) and
A representative image is shown, and a quantification is given below the figure. (G, top)
ce comparing patient 6 and all other samples: not significant. Significance comparing
ogen. Significance comparing classic infantile versus the childhood, adult, and healthy
patient 6 versus healthy control: p = 0.052). Both assays were performed on the same
wed by a 24h starvation to clear intracellular glycogen. GAA activity is shown as a
iants identified in patient 6. Error bars in G indicate S.D.
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Table 3. Novel Variants Identified with Proof of Pathogenicity
Disease-Associated Variant on Allele 1 Disease-Associated Variant/Event on Allele 2 Proof of Pathogenicity for Novel Variant
Patient 1 c.2331+2T>A c.1327-61_1437+171dela
resulting deletion in the transcript is known to
cause a deﬁciency of GAA
Patient 2 c.-32-13T>G
17 kb deletion, including promoter and
transcription start site of GAAa
no RNA expression originating from the allele
containing the deletion
Patients 3, 4, and 5
c.-113+2T>Aa
+ c.2065G>Ab
c.-113+2T>Aa
+ c.2065G>Ab
expression and splicing analysis of variant in
minigene model
Patient 6 c.925G>A mosaicism c.925G>Aa
SNP arrays of different tissues, Sanger sequencing,
glycogen accumulation assay
aNovel variants.
bPseudodeﬁciency variant.
www.moleculartherapy.orgthe c.925G>A variant in a heterozygous state, which results in a
healthy cell population. To conﬁrm this further, two protein-based
assays were performed to examine the biochemical properties of the
patient’s cells. Figure 4G shows the results of the glycogen accumula-
tion and GAA activity assays, which were performed on the same
cellular extract. Patient ﬁbroblasts accumulated intracellular
glycogen, a characteristic that normally only occurs in vitro in ﬁbro-
blasts derived from classic infantile Pompe patients but not in late-
onset patients. However, GAA enzymatic activity (Figure 4G) was
present and in the range of late-onset Pompe disease. This is in agree-
ment with a genetic mosaicism with the sample consisting of two cell
populations: one that accumulates glycogen in vitro and one that still
possesses enzymatic GAA activity and thereby does not accumulate
glycogen.
In summary, the atypical phenotype for Pompe disease presented by
patient 6 can be explained by a genetic mosaicism for a segment of
chromosome 17 that includes GAA. It is likely that in cardiac cells,
the contribution of homozygous cells to heart tissue is relatively large,
causing a LVH. In skeletal muscle cells, the mixture of homozygous
and heterozygous nuclei in muscle ﬁbers likely causes only mild
pathology.
DISCUSSION
Conventional diagnostic procedures are able to identify and diagnose
most individuals with Pompe disease; however, a number of cases
remain unexplained.4 Here, we emphasize the need to introduce
new methods in the diagnostic validation of Pompe disease in cases
for which conventional procedures prove insufﬁcient. With the use
of extended diagnostic analyses, we identiﬁed three new variants in
the GAA gene. With the use of minor adjustments to already-existing
assays, we proved the pathogenicity of the variants and completed the
diagnosis for six cases of Pompe disease derived from four families
(Table 3).
In previous work, the exon-ﬂanking RT-PCR analysis proved useful
to identify novel variants located outside the coding regions, for
example, as shown by the identiﬁcation of c.2190-345A>G.9 Here,
we showed this assay to be capable of detecting novel deletions and
revealing differential gene expression as a result of GAA variants.MoleculHowever, the 17kb deletion in patient 2 and thereby other deletions
spanning more than one exon remained undetected, and additional
assays were required. To detect the deletion of exon 18, which is a
common variant in Caucasian patients with Pompe disease, our diag-
nostic center performs a separate PCR reaction.28 However, other
large deletions are not routinely analyzed and will therefore not be
identiﬁed. This is supported by the under-representation of gross de-
letions and other types of variants, such as promoter variants in
GAA.10,29,30 As described in the Human Gene Mutation Database
(HGMD), gross deletions represent 7.5% of all disease-associated var-
iants, whereas approximately 1% of all disease-associated variants are
reported to be located in promoter regions genome wide.29 For
Pompe disease, gross deletions constitute only 1.5% of known vari-
ants, and the variants described here in patients 2 and 3 represent
the ﬁrst reported disease-associated variants located in the promoter
and 50 UTR regions of GAA.10 These regions are critical for the regu-
lation of gene expression, and we recommend these regions to be
included in future diagnostic analyses. The detection of non-coding
variants can be improved with the implementation of techniques
already established in many diagnostic laboratories as a follow-up
to DNA sequencing. SNP array analysis allows for the detection of
large deletions or duplications, whereas aberrant splicing events or se-
vere reductions in gene expression can be detected using whole tran-
scriptome sequencing.18,31 Other existing techniques can also be im-
plemented for speciﬁc monogenic disorders and are capable of
detecting smaller aberrations. Multiplex ligation-dependent probe
ampliﬁcation (MLPA) can detect deletions affecting single exons,
whereas exon-ﬂanking RT-PCR can be performed to detect deletions,
splicing aberrations, and differential gene expression.9,18 A more sys-
tematic approach, as described above, could lead to the identiﬁcation
of new disease-associated variants and provide a complete DNA diag-
nosis for patients. The implementation of the approaches outlined
here should therefore be considered to improve the genetic analysis
of cases with an unexplained genetic diagnosis.
Patients with an atypical phenotype often represent a challenge when
diagnosing genetic disorders. Patient 6 presented a unique pathological
condition: LVH, a characteristic usually observed only in the classic in-
fantile phenotype, while lacking any sign of muscle weakness after 4
years of age. This phenotype was corroborated by the differences inar Therapy: Methods & Clinical Development Vol. 17 June 2020 345
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analysis, we detected a chromosomal imbalance on chromosome 17,
which was crucial to identify the genetic mosaicism of Pompe disease.
Genetic mosaicisms are often associatedwith amilder symptomatology
due to the presence of a healthy or less affected cell population.32
The mosaicism in patient 6 appears to be the result of a segmental
UPD. UPDs have been associated with many inherited disorders
and appropriately explain a subset of patients carrying homozygous
disease-associated variants.33 Whole-chromosome UPDs are re-
ported to occur in 1/3,500 births,33 whereas segmental UPDs occur
less frequently and are the result of somatic recombination.34–36
The mosaic nature of the segmental UPD and the high percentage
of affected cells in several of the patient tissues suggest that the recom-
bination event occurred early in the postzygotic stage of embryonal
development.34–36 Tissues of this patient were thereafter comprised
of two cell populations, with the c.925G>A disease-associated variant
being present at either a heterozygous (healthy) or homozygous
(classic infantile) state.
The presence of a population of healthy cells in the patient did not pre-
vent the development of LVH, which normally only occurs in classic
infantile patients. However, at 4 years of age, the patient has not yet
manifested any other symptoms related to Pompe disease. The lack
of muscle weakness in this patient was reﬂected by mild pathology in
his muscle biopsies. This is likely due to the multinucleation of muscle
ﬁbers, whereby the genetic mosaicism in this patient is offset by the
presence of both affected and unaffected nuclei in individual muscle ﬁ-
bers, which could be sufﬁcient to prevent muscle pathology. A compre-
hensive follow-up of this patient, including CNS magnetic resonance
imaging (MRI) and neuropsychological investigations, will be required
to rule out additional symptoms, such as white matter changes in the
brain, which can manifest in classic infantile Pompe patients.37,38
This study shows the need for the implementation of additional diag-
nostic assays and research as a follow-up when conventional proced-
ures prove insufﬁcient or when a patient’s symptoms or biochemical
characteristics do not match to a disorder. For monogenic disorders,
such as Pompe disease, more speciﬁc assays can be implemented for
an improved analysis of a singular gene. The implementation of this
follow-up will likely result in the identiﬁcation of novel variants and
provide a complete DNA diagnosis for patients carrying non-coding
variants.MATERIALS AND METHODS
Patients
The patients described here were selected for their clinical and/or
biochemical diagnosis that could be attributed to a deﬁciency of
GAA. Informed consents were obtained to perform extended diag-
nostic assays to identify GAA variants and explain the presented phe-
notypes. Analysis of the patients analyzed in this study was approved
by the medical ethics committee of the Erasmus MC. Primary ﬁbro-
blasts were not available for patient 4 and 5, assays were performed for346 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2patient 3, and ﬁndings were thereafter conﬁrmed in DNA from pa-
tients 4 and 5.
DNA Analysis
GenBank: NM_001079803.2 and NM_0001079803.2 were used as
reference sequences for GAA DNA and mRNA, respectively, where
c.1 represents the ﬁrst nucleotide of the translation start codon
ATG. NP000143.2 was used as a reference for GAA protein. We
note that in previous annotations, exon 1 comprised 334 nt, whereas
in current annotations, this region is divided into two exons (exon 1A
and 1B) and a 185-nt intron. All SNP arrays analyses were performed
using the Illumina Inﬁnium CytoSNP-850K BeadChip platform.
Analysis of genes related to genetic disorders located within speciﬁed
genomic regions was performed using Genomic Oligoarray and SNP
Array Evaluation Tool v3.0.
Histology and Imaging
Acid phosphatase staining was performed on cryosections, as
described.39 PAS staining was performed on sections of glycolme-
thacrylate (GMA)-processed tissue.24 Hematoxylin and eosin
(H&E) stainings were performed on both GMA ﬁxated and cryosec-
tions. A Hamamatsu NanoZoomer 2.0 (Hamamatsu Photonics) was
used for imaging, and images were analyzed with NDP.view
software.
RNA Isolation and cDNA Synthesis
Total RNA was isolated from cultured ﬁbroblasts using the RNeasy
minikit (QIAGEN), including a DNaseI (QIAGEN) treatment. RT-
PCR was performed using the iScript cDNA synthesis kit (Bio-Rad)
in reactions with 300–800 ng RNA input.
PCR and Sanger Sequencing
RT-PCR and qRT-PCR were performed as described.9 Sanger
sequencing of PCR products was performed using a ABI3730XL
DNA analyzer (Thermo Fisher Scientiﬁc) and analyzed using ApE
software.
Generation of the Minigene Constructs and Transfection
The minigene model described in Bergsma et al.12 was modiﬁed as
follows: with the use of a primer with a XhoI overhang and a SBF1
restriction site, the exon 1a region was ampliﬁed and cloned in the
construct. We used the QuikChange II Site-Directed Mutagenesis
Kit (Agilent Technologies) to introduce the c.-113+2T>A variant.
Transfection of the minigene constructs was performed in
HEK293T cells using Lipofectamine 2000 (Invitrogen). RNAwas har-
vested 48 h after transfection.
Enzyme Activity and Glycogen Assay
GAA activity wasmeasured in leukocytes or ﬁbroblasts using 4MU, as
described.9 All 4MU assays were performed in diagnostic settings,
with the exception of Figure 4G. For this experiment, ﬁbroblasts
had been conﬂuent for 3 weeks and starved in glucose-free medium,
24 h before harvest, after which, GAA activity was measured using the020
www.moleculartherapy.org4MU.9 Intracellular glycogen was measured with a two-step protocol
using amylase and glucose-oxidase.9
Fragment Analysis of Microsatellite Markers
15 probes were selected for their location on chromosome 17. Anal-
ysis of the VIC- or FAM-labeled products was performed using an
ABI3730XL DNA analyzer (Thermo Fisher Scientiﬁc).
Fluorescence In Situ Hybridization Analysis
FISH was performed on cultured ﬁbroblasts at a low passage number.
Two probes located on 17p12 and 17q22 were used to visualize both
ends of the chromosome. The cells were not conﬂuent when ﬁxed and
classiﬁed as having a normal karyotype when two or four copies of
each probe were visible.
Statistics
Data were analyzed using IBM SPSS statistics, version 26. For all ex-
periments, normal distribution of data was determined based on
calculated residuals. Signiﬁcance between normally distributed data
from two groups was tested using an unpaired two-tailed t test. For
experiments with three or more groups, a one-way ANOVA of inde-
pendent samples with Tukey honestly signiﬁcant difference (HSD) or
Games-Howell post hoc multiple correction (depending on homoge-
neity of the variance) was performed. Non-normal distributed data
were statistically tested using the Kruskal-Wallis method of indepen-
dent samples with Bonferroni multiple comparison for three or more
groups. A p value of less than 0.05 was considered signiﬁcant for all
tests.
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